Galderma S.A.
http://www.galderma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galderma S.A.
Galderma Hopes To Break Into Prurigo Nodularis Market, But May Face Rivals
The dermatology specialist announced positive results from the OLYMPIA 2 trial of nemolizumab, but Sanofi and Regeneron are already pursuing a similar indication for Dupixent.
Bigger Money: Private Equity Grabs European VC
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?
Keeping Track: Pediatric Approvals, Seres Starts C Diff Submission, And BMS Pulls Reblozyl sBLA Before Possible CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
India Proposes OTC List In Draft Rule Lacking Clarity On Pricing, Switching Pathway
India puts out rules for first set of over-the-counter drugs but provides no specifics on the pricing policy for such products or the wider switching pathway. Can the framework foster responsible self-medication and help reap value for patients in a market where the oversight of trade channels for sale of prescription-based drugs is lax?
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Other Names / Subsidiaries
-
- Alastin Skincare, Inc.
- CollaGenex Pharmaceuticals, Inc., Nestle S.A.
- Nestle Skin Health S.A.
- Spirig Pharma AG
- Q-Med AB